DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Abciximab does not prevent ischemic lesions related to cerebral angiography: a randomized placebo-controlled trial.

Author(s): Brockmann C, Hoefer T, Diepers M, Neumaier-Probst E, Noelte I, Brockmann MA, Weiss C, Groden C, Scharf J

Affiliation(s): Department of Neuroradiology, Medical Faculty Mannheim, University of Heidelberg, Germany. caro.brockmann@gmx.de

Publication date & source: 2011, Cerebrovasc Dis., 31(4):353-7. Epub 2011 Jan 7.

Publication type: Randomized Controlled Trial

BACKGROUND: To assess the efficiency of IIb/IIIa platelet receptor inhibition by abciximab in the prevention of silent embolism during digital subtraction angiography. METHODS: In this randomized, double-blind, prospective study, pre- and postangiographic diffusion-weighted magnetic resonance imaging (DWI) of 184 participants was evaluated for the occurrence of silent embolism. RESULTS: No significant relationship was found between the patients receiving abciximab before digital subtraction angiography (15 of 90; 16.7%) and patients in the placebo group (16 of 94; 17.0%) regarding postangiographic appearance of silent emboli (p = 0.9). CONCLUSIONS: IIb/IIIa receptor inhibition by abciximab does not diminish the occurrence of silent embolism during digital subtraction angiography. Our findings indicate that solid blood clots are not the origin of hyperintense lesions observed on DWI and enhance the role of alternative mechanisms. Copyright (c) 2011 S. Karger AG, Basel.

Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017